CG Oncology Commence Late-Stage Study for Bladder Cancer Treatment

CG Oncology has started a third stage study for cretostimogene to treat intermediate-risk non-muscle invasive bladder cancer. 

Intermediate-risk non-muscle invasive bladder cancer refers to a stage of bladder cancer where the tumor has not invaded the muscle layer but carries an increased risk of recurrence or progression. 

If the candidate shows no signs of cancer relapse symptoms at three months, they will receive extended treatment in months three, six, nine and twelve. 

The main goal of the trial is to assess overall symptom relapse, with additional measurements at the one-year and two-year mark. 

Arthur Kuan, the head executive at CG Oncology, stated, “The dosing of the first patient in our PIVOT-006 trial advances cretostimogene earlier in the treatment paradigm for NMIBC patients who face limited treatment options, frequent disease recurrence, and repetitive surgery.” 

Kuan went on to add, “Our goal with the PIVOT-006 trial is to advance cretostimogene as a potential backbone oncolytic immunotherapy.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.